Combination of 2-Chlorodeoxyadenosine, Cytarabine, and Granulocyte Colony-Stimulating Factor and Venetoclax in a Case of Acute Myelogenous Leukemia.

Ella Prebel Jackert, Karrune Woan, Preet Chaudhary, George Yaghmour, Abdullah Ladha, Eric Tam

Abstract readCase Reports

In one paragraph

Article in Journal of medical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ella Prebel JackertKeck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.

Karrune WoanDepartment of Bone and Marrow Transplant, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.

Preet ChaudharyDepartment of Bone and Marrow Transplant, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.

George YaghmourDepartment of Bone and Marrow Transplant, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.

Abdullah LadhaDepartment of Bone and Marrow Transplant, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.

Eric TamDepartment of Bone and Marrow Transplant, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The high rates of relapse following induction therapy for acute myelogenous leukemia (AML) warrant the investigation of novel chemotherapy regimens to better treat the disease safely. We report a case of refractory AML treated with CLAG (a combination of 2-chlorodeoxyadenosine, cytarabine, and granulocyte colony-stimulating factor (GCSF)), as a replacement for FLAG-IDA (fludarabine, cytarabine, G-CSF and idarubicin), due to a shortage of fludarabine, plus B-cell lymphoma-2 (BCL-2) inhibitor venetoclax (CLAG + VEN). A 38-year-old woman with a past medical history of systemic lupus erythematosus (SLE), managed on hydroxychloroquine, presented to her primary care provider with worsening fatigue and was found to have significant leukocytosis. The patient was diagnosed with AML on bone marrow biopsy (BMBX). The patient delayed care after the initial diagnosis but eventually started on a continuous infusion of cytarabine for therapy day (D) 1 - D7 and daunorubicin 60 mg/m

Indexed as

Acute myelogenous leukemiaBone marrow transplantCLAGInduction chemotherapyVenetoclax

Identifiers

PMID40160192

DOI10.14740/jmc5087

PMCPMC11954599

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.